AI in drug discovery
AI in drug discovery (also called AI drug discovery) is the application of artificial intelligence, machine learning, deep learning, generative models, and natural language processing across the pharmaceutical…
Explore AI for Science through related topics and the articles other pages reference most.
Articles that also belong to these categories. Counts cover all of AI for Science.
Showing 1-12 of 12 articles
AI in drug discovery (also called AI drug discovery) is the application of artificial intelligence, machine learning, deep learning, generative models, and natural language processing across the pharmaceutical…
AlphaGenome is a unified deep learning model developed by Google DeepMind that predicts thousands of functional genomic properties from raw DNA sequences.
AlphaGenome Atlas is a precomputed catalog of molecular-effect predictions for genetic variants, released by Google DeepMind on September 8, 2026.
AlphaMissense is a machine learning model from Google DeepMind that predicts whether a missense variant, a single amino-acid substitution in a protein, is likely to cause disease.
A brain-computer interface (BCI), also called a brain-machine interface, is a system that measures activity in the nervous system and translates it into commands for an external device, bypassing muscles and…
C-BRAIN (the Consortium for Biomedical Research and AI in Neurodegeneration, styled "C-brAIn" in early coverage) is a consortium of academic researchers, pharmaceutical companies, philanthropic organizations…
CRISPR is a family of gene-editing tools derived from a bacterial immune system.
The Chan Zuckerberg Initiative (CZI) is the philanthropic organization founded in December 2015 by Mark Zuckerberg, the founder and chief executive of Meta, and his wife Priscilla Chan, a pediatrician.
NewLimit is an American biotechnology company, headquartered in South San Francisco, California, that is developing medicines intended to restore youthful function to old cells through epigenetic reprogramming.
Protein design is the construction of new protein sequences that fold into an intended three-dimensional shape and perform an intended job, such as binding a chosen target, catalyzing a reaction, or assembling…
Rentosertib is an investigational oral small-molecule inhibitor of TNIK (TRAF2- and NCK-interacting kinase) developed by Insilico Medicine for idiopathic pulmonary fibrosis (IPF)
The Virtual Biology Initiative is a five-year research program launched on April 29, 2026 by Biohub, the science organization of the Chan Zuckerberg Initiative (CZI), with a founding commitment of $500 million.